Literature DB >> 18292806

Currying favor for the heart.

Jonathan A Epstein1.   

Abstract

Curcumin, a commonly available spice and alternative medicine, has been tested in the laboratory and the clinic for activity against a wide range of diseases. It is thought to possess antiinflammatory and antioxidant activities and may also function to inhibit histone acetyl transferases, which activate gene expression via chromatin remodeling. Two reports in this issue of the JCI, by Morimoto et al. and Li et al., suggest that curcumin may inhibit cardiac hypertrophy in rodent models and provide beneficial effects after myocardial infarction or in the setting of hypertension (see the related articles beginning on pages 868 and 879, respectively). These results will spur further mechanistic inquiry into the role of chromatin remodeling in the regulation of cardiac homeostasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292806      PMCID: PMC2248428          DOI: 10.1172/JCI34650

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

Review 1.  Myocardial protection at a crossroads: the need for translation into clinical therapy.

Authors:  Roberto Bolli; Lance Becker; Garrett Gross; Robert Mentzer; David Balshaw; David A Lathrop
Journal:  Circ Res       Date:  2004-07-23       Impact factor: 17.367

Review 2.  Correction of the CF defect by curcumin: hypes and disappointments.

Authors:  Marcus Mall; Karl Kunzelmann
Journal:  Bioessays       Date:  2005-01       Impact factor: 4.345

3.  The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity.

Authors:  Rosalind J Gusterson; Elen Jazrawi; Ian M Adcock; David S Latchman
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

4.  Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes.

Authors:  Teruhisa Kawamura; Koh Ono; Tatsuya Morimoto; Hiromichi Wada; Maretoshi Hirai; Kyoko Hidaka; Takayuki Morisaki; Toshio Heike; Tatsutoshi Nakahata; Toru Kita; Koji Hasegawa
Journal:  J Biol Chem       Date:  2005-03-13       Impact factor: 5.157

5.  Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.

Authors:  Hae Jin Kee; Il Suk Sohn; Kwang Il Nam; Jong Eun Park; Yong Ri Qian; Zhan Yin; Youngkeun Ahn; Myung Ho Jeong; Yung-Jue Bang; Nacksung Kim; Jong-Keun Kim; Kyung Keun Kim; Jonathan A Epstein; Hyun Kook
Journal:  Circulation       Date:  2005-12-27       Impact factor: 29.690

Review 6.  Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.

Authors:  William Kevin Kelly; Paul A Marks
Journal:  Nat Clin Pract Oncol       Date:  2005-03

7.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Authors:  Hyun Kook; John J Lepore; Aaron D Gitler; Min Min Lu; Wendy Wing-Man Yung; Joel Mackay; Rong Zhou; Victor Ferrari; Peter Gruber; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.

Authors:  Karanam Balasubramanyam; Radhika A Varier; Mohammed Altaf; Venkatesh Swaminathan; Nagadenahalli B Siddappa; Udaykumar Ranga; Tapas K Kundu
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

9.  Cardiac p300 is involved in myocyte growth with decompensated heart failure.

Authors:  Tetsuhiko Yanazume; Koji Hasegawa; Tatsuya Morimoto; Teruhisa Kawamura; Hiromichi Wada; Akira Matsumori; Yosuke Kawase; Maretoshi Hirai; Toru Kita
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

10.  Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.

Authors:  Shurong Chang; Timothy A McKinsey; Chun Li Zhang; James A Richardson; Joseph A Hill; Eric N Olson
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

View more
  6 in total

Review 1.  Timing and Targeting of Treatment in Left Ventricular Hypertrophy.

Authors:  Deokhwa Nam; Erin L Reineke
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Jan-Mar

2.  Protective effect of curcumin on pulmonary and cardiovascular effects induced by repeated exposure to diesel exhaust particles in mice.

Authors:  Abderrahim Nemmar; Deepa Subramaniyan; Badreldin H Ali
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

3.  Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells.

Authors:  Tatiana N Sidorova; Liudmila V Yermalitskaya; Lisa C Mace; K Sam Wells; Olivier Boutaud; Joseph K Prinsen; Sean S Davies; L Jackson Roberts; Sergey I Dikalov; Charles G Glabe; Venkataraman Amarnath; Joey V Barnett; Katherine T Murray
Journal:  J Mol Cell Cardiol       Date:  2014-11-18       Impact factor: 5.000

4.  Curcumin suppresses gelatinase B mediated norepinephrine induced stress in H9c2 cardiomyocytes.

Authors:  Shrey Kohli; Aastha Chhabra; Astha Jaiswal; Yashika Rustagi; Manish Sharma; Vibha Rani
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

5.  Histone deacetylase inhibitors as novel anticancer therapeutics.

Authors:  D R Walkinshaw; X J Yang
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

6.  High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy.

Authors:  Antoinette Bugyei-Twum; Andrew Advani; Suzanne L Advani; Yuan Zhang; Kerri Thai; Darren J Kelly; Kim A Connelly
Journal:  Cardiovasc Diabetol       Date:  2014-05-05       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.